Respiratory syncytial virus vaccine

Therapeutic indications

Respiratory syncytial virus vaccine is indicated for:

Lower respiratory tract disease (LRTD) caused by respiratory syncytial virus - RSVPreF3 vaccine

Population group: only adults (18 years old or older)

Adjuvanted RSVPreF3 vaccine is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in:

  • adults 60 years of age and older;
  • adults 50 through 59 years of age who are at increased risk for RSV disease.

The use of this vaccine should be in accordance with official recommendations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2025: mRESVIA Dispersion for injection
Summary of Product Characteristics (SPC) 2025: ABRYSVO Powder and solvent for solution for injection
Summary of Product Characteristics (SPC) 2024: AREXVY Powder for suspension for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈